Moleac, a biopharmaceutical company based in Singapore, is dedicated in finding, developing, and commercializing new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries. From stroke, traumatic brain injury (TBI) and dementia, the company’s main goal is to help people with disabilities after brain injuries or neurodegenerative diseases—as well as their families—reconnect with their lives.
Moleac has pioneered a new drug development approach that looks at sources of innovation from natural medicine, thus considerably shortening drug development cycle time and investment to bring medicine to post-stroke recovery patients. The company scientifically selected natural compounds and formulations from traditional medicine and developed them according to international standards. This is one of the reasons why Moleac chose to be based in Singapore, which represents a hub within the Asia-Pacific region where traditional medicines originated and has close links with the rest of the world.
Building on this success, the company expanded their worldwide presence from Singapore and developed a new herbal formulation (MLC1501) in post-stroke recovery. An Investigational New Drug application (IND) has been opened by US-Food and Drug Administration (USFDA), which allowed them to conduct two safety studies of MLC1501 in healthy volunteers (Phase 1). With an overall clinical development plan that hypothesizes MLC1501’s effectiveness in improving functional and motor independence and recovery of neurological impairments in post-AIS survivors having not received or not recovered after acute treatments (thrombolysis, thrombectomy).